Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosesimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
DetailsGUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosesimilars,today announced the company has reached an exclusivecommercialization and license agreement with IntasPharmaceuticals for BAT2506, a golimum...
Bio-TheraSolutions, a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosesimilars hassigned an exclusive License and Commercialisation Agreement with WorldMedicine , Türkiye'spharmaceutical export champion, continuingits mission of providing accessible an...
Guangzhou, China – Bio-Thera Solutions, Ltd. today announced thepublication of the Phase Iclinical study results for BAT4406F, an ADCC-enhanced fully humanized anti-CD20monoclonal antibody in Chinese patients with neuromyelitis optica spectrumdisorders (NMOSD) in the journal CNS Neuroscience Thera...
